Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm Block 2 > 6 - Thrombolytic Agents > Flashcards

6 - Thrombolytic Agents Flashcards

1
Q

What is usually the triggering event in an MI? What is needed to treat this?

A

Obstruction of coronary artery by thrombus.

Thrombolytics for reperfusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is fibrinolysis and how is it done?

A

Dissolving intracellular clots.

Plasminogen converted to active plasmin to break down clots.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the mechanism of activation of plasminogen to plasmin?

A

Cleavage of a single peptide Arg560 bond generates two chain disulfide linked molecules and exposes kringles that can bind fibrin to degrade it.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What endogenous molecules activate plasminogen to plasmin? What exogenous drugs activate plasminogen to plasmin?

A

Endogenous: t-PA and Prourokinase

Exogenous: Alteplase (recombinant t-PA) and Tenecteplase (recombinant t-PA).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the action of tissue-type plasminogen activator (t-PA)? What occurs in the early stages of clot formation?

A

Cleaves plasminogen to plasmin.

Early stages of clot formation: inhibitor of plasminogen activator called t-PA-I present (prevents plasmin from being made when you wanna clot.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What happens to free plasmin?

A

Inactivated by alpha2-antiplasmin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What tissue plasminogen activator is produced by recombinant DNA technology, has a very short half life, and requires IV infusion?

A

Alteplase.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What tissue plasminogen activator is produced by recombinant DNA technology, has a longer half life, requires a single bolus administration, and is resistant to inhibition by PAI-1?

A

Tenecteplase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the advantage of fibrin specificity?

A

It limits systemic lysis/increases bleeding risk.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are complications of thrombolytic therapy?

A

Hemorrhage (just as common with t-PA)

More bleeding complications when combined with heparin a/o aspirin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are therapeutic indications for thrombolytic therapy?

A

Acute MI (STEMI).

Complete occlusion of an epicardial coronary vessel caused by an acute thrombotic obstruction. (the earlier the better)

Stroke (only alteplase) - within first 3 hours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What drug inhibits fibrinolysis? How does it do this?

A

Aminocaproic acid: blocks the binding of plasmin to fibrin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does platelet aggregation occur?

A
  1. GP1b, GP1a/IIa glycoprotein receptor proteins (integrins) bind collagen,
  2. GPIIb/GPIIIa glycoprotein receptor binds fibrinogen
  3. P2Y/P2Y12: purinergic receptors for ADP
  4. COX mediated production of TXA2.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the function of low-dose aspirin in platelets? What about in endothelial cells?

A

Irreversibly acetylates COX1 in platelets (no COX2 in platelets) and thereby blocks thromboxane production.

In endothelial cells it irreversibly inhibits COX1 and COX2. Endothelial ells produce prostacyclin which inhibit platelet agreggation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Patients with cardiovascular disease taking aspirin experienced ____% fewer deaths. For combined fatal and nonfatal events the aspirin group was ____% lower than the placebo.

A

30%

21%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the therapeutic uses of low dose aspirin?

A

MI prophylaxis

Stroke prophylaxis

17
Q

What is the function of dipyridamole?

A

Vasodilator and inhibitor of platelet aggregation.

18
Q

What drug inhibits phosphodiesterase, thereby increasing cAMP in platelets and inhibiting platelet aggregation? What is the therapeutic use?

A

Dipyridamole

Used in combo with aspirin for secondary prevention or MI or stroke.

19
Q

What drugs act through P2Y1/P2Y12 receptors to inhibit ADP-induced platelet aggregation? Which are irreversible?

A

Clopidogrel
Ticlopidine
Prasugrel
Ticagrelor

All irreversible except ticagrelor is reversible.

20
Q

Two patients need treatment for acute coronary syndrome. Patient 1 is given clopidogrel. Patient 2 is given ticagrelor. Which drug provides the advantage if the patient requires coronary bypass surgery?

A

Ticagrelor, because it’s reversible.

The patients taking clopidogrel would need to wait until their platelet function returns to normal before having surgery otherwise they could have bleeding complications.

21
Q

How are Clopidogrel, Ticlopidine, Prasugrel and Ticagrelor given? Which are prodrugs and how are they activated?

A

Oral admin.

Prasugrel prodrug: activated via hydrolysis then CYP3A4 and 2B6 activation.

Clopidogrel and Ticlopidine prodrugs: activated by CYP2C19.

22
Q

How does Prasugrel differ from the other drugs act through P2Y1/P2Y12 receptors to inhibit platelet aggregation?

A

It has increased potency because there’s more efficient generation of active metabolite.

More predictable effects on platelets than other P2Y antagonist drugs.

23
Q

What adverse effects are associated with clopidogrel?

A

CYP2C19 polymorphisms cause poor metabolizers that don’t get as much active drug (because clopidogrel is a prodrug).

24
Q

What drugs are given via IV preparations and antagonize GbIIb/IIIa (integrin) receptors?

A

Abciximab and Eptifibatide

25
Q

What is Abciximab? What is its mechanism of action? How is it given?

A

A fab fragment that prevents binding of fibrinogen, vW factor, and other adhesive molecules.

Blocks access of molecules to the receptor via steric hindrance.

Given IV: quick onset, delayed clearance (effective up to 7 days).

26
Q

What is the function of Eptifibatide? How is it given?

A

Binds specifically to GP IIb-IIIa receptors on the platelet surface, thereby blocking the binding of fibrinogen activated platelets.

Given IV: quick onset and offset (platelets normal within 8 hrs of stopping drug).

27
Q

What is the clinical use of Eptifibatide and Abciximab?

A

Pts undergoing percutaneous coronary intervention (PCI), including angioplasty or stent placement.

28
Q

What drug should you be thinking about with acute DVT or pulmonary embolism?

A

Heparin

29
Q

What drugs should you be thinking about with chronic prevention of DVT or PE?

A

Warfarin or NOAC

30
Q

What drugs should you be thinking about with acute coronary syndrome? What about to prevent this?

A

Thrombolytics

Prevention: aspirin

31
Q

What drugs should you be thinking about with stroke? What about to prevent this?

A

Thrombolytics if within 3 hrs.

Prevention: aspirin

32
Q

What drugs should you be thinking about with atrial fibrillation?

A

Warfarin or NOAC (unless there’s an artificial valve then think warfarin)

Pharm Block 2 (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions